Focusing more in detail on clinical trials currently active, Nelarabine was recently well tolerated in combination with the chemotherapy regimen Hyper-CVAD in the treatment for T-ALL (115), and its activity is involved significantly in the modulation of different signaling networks, mainly by targeting aberrant PI3K/AKT/mTOR signaling pathway (111, 116). The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.